What question did this study set out to answer?

This research aims to identify the link between chronic inflammation and mitochondrial dysfunction in Long COVID, focusing on SIRT1 and PGC-1α.

January 22, 2026Open Access

Six Roads to One Target: SIRT1-PGC-1α Convergence Therapy for Long COVID

Key Points

This research aims to identify the link between chronic inflammation and mitochondrial dysfunction in Long COVID, focusing on SIRT1 and PGC-1α.
Analyzed data from the Sovereign Discovery Engine involving 3,137 triplets from 98 studies.
Identified SIRT1-PGC-1α as critical for mitochondrial impairment amid chronic inflammation.
Evaluated six distinct interventions affecting mitochondrial biogenesis and SIRT1 activity.
SIRT1 repression was found to correlate with 66% PGC-1α inhibition due to chronic inflammation.
Interventions showed various levels of efficacy: NMN increased SIRT1 by 100-fold, while others also restored PGC-1α and improved fatigue significantly.
Hyperbaric oxygen therapy led to a 77% improvement in fatigue, evidencing SIRT1's role.

Abstract

Background: Long COVID fatigue affects 50–80% of patients and correlates with mitochondrial dysfunction.Previous work established the Toll-NF-κB inflammatory cascade Paper II and SSRI serotonergic mechanisms PaperI. This paper identifies the upstream regulator linking chronic inflammation to mitochondrial impairment. Discovery: The Sovereign Discovery Engine (3,137 triplets from 98 papers) identified SIRT1-PGC-1α as a criticalconvergence node. Chronic inflammation causes 66% PGC-1α repression, directly impairing mitochondrial biogenesis.Remarkably, six independent interventions—all with quantified efficacy—converge on this same pathway. The Six Roads: (1) NMN supplementation (100-fold SIRT1 increase); (2) EGCG/Green tea (SIRT1/PGC-1αupregulation at 5 mg/kg); (3) Resveratrol (50% PGC-1α restoration); (4) Curcumin (2-fold SIRT1 via AMPK-NAD+); (5) Quercetin (17% mitochondrial biogenesis); (6) Hyperbaric Oxygen Therapy (77% fatigue improvement,SIRT1-mediated). Significance: The convergence of six mechanistically distinct interventions on one pathway is not cherry-picking—itis pattern recognition. All compounds are OTC/supplement-category with established safety profiles. HBOT providesnon-pharmacological cross-validation. This suggests a multi-compound protocol for mitochondrial restoration inLong COVID.

Six Roads to One Target: SIRT1-PGC-1α Convergence Therapy for Long COVID

Key Points

Abstract

Cite This Study